• Inhibition
  • Major adverse cardiac events (MACEs: composite of death, myocardial infarction, and urgent target vessel revascularization) were prospectively monitored, and the incidence correlated with the measured level of platelet function inhibition at all time points. (ahajournals.org)
  • By multivariate analysis, platelet function inhibition ≥95% at 10 minutes after the start of therapy was associated with a significant decrease in the incidence of a MACE (odds ratio 0.46, 95% CI 0.22 to 0.96, P =0.04). (ahajournals.org)
  • The level of platelet function inhibition as measured by a point-of-care assay is an independent predictor for the risk of MACEs after PCI. (ahajournals.org)
  • The recent development of a rapid, whole-blood, point-of-care platelet function assay, the Ultegra Rapid Platelet Function Assay (RPFA) (Accumetrics, Inc), whose results correlate well with turbidimetric aggregometry and receptor-binding assays, now allows for the monitoring of platelet inhibition in much larger populations than previously possible. (ahajournals.org)
  • 5 Using this device, we previously found substantial interpatient variability in platelet inhibition among patients undergoing a percutaneous coronary intervention (PCI) treated with a standard, weight-adjusted bolus and 12-hour infusion of abciximab, 6 7 with 1 study suggesting a correlation between the level of platelet inhibition and the risk of a periprocedural adverse cardiac event. (ahajournals.org)
  • receptor
  • 2 3 4 Because of the technical constraints of receptor-binding assays and standard turbidimetric platelet aggregometry, however, these studies were limited to only a small number of patients. (ahajournals.org)